Should We Be Concerned About Thyroid Cancer in Patients Taking Glucagon-Like Peptide 1 Receptor Agonists?

Cleveland Clinic Journal of Medicine - United States
doi 10.3949/ccjm.81a.13066
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Cleveland Clinic Journal of Medicine

Related search

Cardiovascular Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2014English

Synthesis and Biological Evaluation of Glucagon-Like Peptide-1 Receptor Agonists

Archives of Pharmacal Research
Organic ChemistryDrug DiscoveryMolecular Medicine
2013English

Effects of Gastric Inhibitory Polypeptide, Glucagon-Like Peptide-1 and Glucagon-Like Peptide-1 Receptor Agonists on Bone Cell Metabolism

Basic and Clinical Pharmacology and Toxicology
MedicineToxicologyPharmacology
2017English

Glucagon-Like Peptide 1 Receptor Agonists: A New Approach to Type 2 Diabetes Management

South African Family Practice
2013English

Glucagon-Like Peptide-1 Receptor Agonists Increase Pancreatic Mass by Induction of Protein Synthesis

Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2014English

Equine Glucagon-Like Peptide-1 Receptor Physiology

PeerJ
GeneticsMolecular BiologyBiochemistryBiological SciencesMedicineAgriculturalNeuroscience
2018English

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

Gastroenterology
HepatologyGastroenterology
2011English

Sports Injuries in Children: Should We Be Concerned?

Archives of Disease in Childhood
Child HealthPediatricsPerinatology
1997English

Glucagon-Like Peptide-1 Receptor (GLP1R; GLP-1R)

Science-Business eXchange
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy